WO2012040223A3 - Method for treating non-alcoholic fatty liver disease and type-ii diabetes - Google Patents

Method for treating non-alcoholic fatty liver disease and type-ii diabetes Download PDF

Info

Publication number
WO2012040223A3
WO2012040223A3 PCT/US2011/052390 US2011052390W WO2012040223A3 WO 2012040223 A3 WO2012040223 A3 WO 2012040223A3 US 2011052390 W US2011052390 W US 2011052390W WO 2012040223 A3 WO2012040223 A3 WO 2012040223A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
type
liver disease
fatty liver
alcoholic fatty
Prior art date
Application number
PCT/US2011/052390
Other languages
French (fr)
Other versions
WO2012040223A2 (en
Inventor
Jonathan Z. Sexton
Jay Brenman
Original Assignee
North Carolina Central University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina Central University filed Critical North Carolina Central University
Publication of WO2012040223A2 publication Critical patent/WO2012040223A2/en
Publication of WO2012040223A3 publication Critical patent/WO2012040223A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This relates generally to compounds that can be used to treat nonalcoholic fatty liver disease and type II diabetes and an assay for identifying the compounds. The invention also relates to an assay that can be used to identify compounds that increase cellular peroxisomal mass.
PCT/US2011/052390 2010-09-21 2011-09-20 Method for treating non-alcoholic fatty liver disease and type-ii diabetes WO2012040223A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38514610P 2010-09-21 2010-09-21
US61/385,146 2010-09-21

Publications (2)

Publication Number Publication Date
WO2012040223A2 WO2012040223A2 (en) 2012-03-29
WO2012040223A3 true WO2012040223A3 (en) 2012-06-07

Family

ID=45874328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/052390 WO2012040223A2 (en) 2010-09-21 2011-09-20 Method for treating non-alcoholic fatty liver disease and type-ii diabetes

Country Status (1)

Country Link
WO (1) WO2012040223A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107205971A (en) 2014-11-18 2017-09-26 罗格斯，新泽西州立大学 New mitochondrial uncoupler for treating metabolic disease and cancer
FR3050936B1 (en) * 2016-05-04 2020-03-27 Apteeus COMPOUND USEFUL FOR TREATING A DEFICIT OF THE CATABOLISM OF VERY LONG CHAIN FATTY ACIDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUND
WO2017201313A1 (en) 2016-05-18 2017-11-23 Shengkan Jin Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ORAZEM ET AL.: "Expression and localization of the enhanced green fluorescent protein in the peroxisomes of the methylotrophic yeast Pichia pastoris", BIOS, vol. 75, no. 4, December 2004 (2004-12-01), pages 147 - 154 *
REUMANN: "Specification of the peroxisome targeting signals type 1 and type 2 of plant peroxisomes by bioinformatics analyses", PLANT PHYSIOL, vol. 135, no. 2, June 2004 (2004-06-01), pages 783 - 800 *
SEXTON J.Z. ET AL: "High content screening for nonclassical peroxisome proliferators", INT. J. HIGH THROUGHPUT SCREEN, vol. 2010, no. 1, 21 July 2010 (2010-07-21), pages 127 - 140 *

Also Published As

Publication number Publication date
WO2012040223A2 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
PH12018500843B1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
WO2011028938A8 (en) Methods for lowering serum cholesterol in a subject using inhibition of pcsk9
WO2010062377A3 (en) Methods and compositions for the detection and treatment of preeclampsia
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
WO2012009644A3 (en) Methods to identify synthetic and natural rna elements that enhance protein translation
WO2012014076A3 (en) Liver organoid, uses thereof and culture method for obtaining them
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2010089411A3 (en) Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2010102267A3 (en) Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
WO2013154826A3 (en) Methods for diagnosing impending diarrhea
EP2141497B8 (en) Method for the analysis of circulating antibodies
WO2012166626A8 (en) Reagents and methods for treating dental disease
WO2013096838A3 (en) Systems and methods for isolating nucleic acids
EP2554669A4 (en) Novel antibody having modification site introduced therein, and antibody fragment
WO2009039337A3 (en) Inhibition of angiogenesis
WO2012048113A3 (en) Biomarkers of cancer
WO2011139973A3 (en) Methods of inhibiting fibrosis using anti-pai-1 antibodies
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
WO2011153234A3 (en) Methods of inhibiting alu rna and therapeutic uses thereof
WO2010025321A3 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
WO2012058220A3 (en) Anti-sod1 antibodies and uses thereof
WO2012003470A3 (en) Antibody formulations
AP2011005905A0 (en) Device and method for the verification and quantitative analysis of analytes, particularly mycotoxins.
WO2009124294A3 (en) Pharmaceutical compositions for binding sphingosine-1-phosphate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11827367

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11827367

Country of ref document: EP

Kind code of ref document: A2